NetworkNewsBreaks – Axsome Therapeutics, Inc. (NASDAQ: AXSM) Featured in Mizuho Securities Research Report
Axsome Therapeutics (NASDAQ: AXSM) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Axsome reported a 4Q20 EPS loss of ($0.78), essentially in line with consensus' ($0.77) but worse than our ($0.60). However, quarterly earnings are not as important as the company hitting its clinical/regulatory milestones. The important positive news was confirmation the AXS-05 NDA in MDD has been filed with the FDA, while the AXS-07 filing in acute migraine was pushed slightly from 1Q 2021 to early 2Q. We expect AXS-05 to obtain a Priority Review, and expect the stock to…







